IMS swings for $100M IPO; China targets lagging manufacturers;

> Pharma consulting outfit IMS Health has filed for a $100 million IPO. News

> The Chinese FDA is cracking down on low-quality drug manufacturers in the region. Article

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.